Fibrocor Therapeutics Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
8
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
5
Fibrocor Therapeutics General Information
Description
Developer of novel medicines designed to identify and target critical pathways in the fibrogenic process. The company leverages patient-derived tissue samples to uncover critical pathways in the fibrogenic process, enabling medical professionals to find novel disease targets and develop a robust pipeline of therapeutics.
Contact Information
Website
www.fibrocor.comCorporate Office
- 661 University Avenue
- Suite 1300
- Toronto, Ontario M5G 0B7
- Canada
Corporate Office
- 661 University Avenue
- Suite 1300
- Toronto, Ontario M5G 0B7
- Canada
Fibrocor Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Accelerator/Incubator | 02-Nov-2023 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC | 15-Jan-2020 | Completed | Pre-Clinical Trials | |||
| 1. Seed Round | 17-Jan-2017 | $2.1M | $2.1M | Completed | Pre-Clinical Trials |
Fibrocor Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Fibrocor Therapeutics Patents
Fibrocor Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024357784-A1 | Compounds and uses thereof | Pending | 13-Oct-2023 | ||
| EP-4791734-A1 | Compounds and uses thereof | Pending | 13-Oct-2023 | ||
| WO-2025076632-A1 | Compounds and uses thereof | Inactive | 13-Oct-2023 | ||
| AU-2023368765-A1 | Antibodies that bind to integrin alpha11 and uses thereof | Pending | 24-Oct-2022 | ||
| EP-4608866-A1 | Antibodies that bind to integrin alpha11 and uses thereof | Pending | 24-Oct-2022 | C07K16/2839 |
Fibrocor Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Fibrocor Therapeutics Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Berkshire Innovation Center | Accelerator/Incubator | |||
| BioGeneration Ventures | Venture Capital | Minority | ||
| Lakefront Biotherapeutics | Corporation | Minority | ||
| Evotec | Corporation | Minority | ||
| Toronto Innovation Acceleration Partners | Accelerator/Incubator | Minority |
Fibrocor Therapeutics FAQs
-
When was Fibrocor Therapeutics founded?
Fibrocor Therapeutics was founded in 2017.
-
Where is Fibrocor Therapeutics headquartered?
Fibrocor Therapeutics is headquartered in Toronto, Canada.
-
What is the size of Fibrocor Therapeutics?
Fibrocor Therapeutics has 8 total employees.
-
What industry is Fibrocor Therapeutics in?
Fibrocor Therapeutics’s primary industry is Drug Discovery.
-
Is Fibrocor Therapeutics a private or public company?
Fibrocor Therapeutics is a Private company.
-
What is Fibrocor Therapeutics’s current revenue?
The current revenue for Fibrocor Therapeutics is .
-
How much funding has Fibrocor Therapeutics raised over time?
Fibrocor Therapeutics has raised $2.1M.
-
Who are Fibrocor Therapeutics’s investors?
Berkshire Innovation Center, BioGeneration Ventures, Lakefront Biotherapeutics, Evotec, and Toronto Innovation Acceleration Partners have invested in Fibrocor Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
